Zimbabwe has rejected a significant US healthcare agreement worth $367m (272 million pounds) spanning five years because of Washington's insistence on confidential biological samples.
This move came to light following a official document dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson later stated that the US was requesting biological samples for scientific study and profit while refused to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to find a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development follows a similar case in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
Based on statements, 16 African countries have to date signed these new health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our citizens if a future health crisis arise."
National Interest and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our US partners on how future collaboration could be structured in a manner that honours the independence and interests of both nations."
Medical Community Response
Medical experts said it understood the official position, but urged that talks should continue given that a large portion of the nation's Aids initiatives relied on international support.
"If specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
This impasse highlights the continuing challenges between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.